Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Methodic aspects of influenza and respiratory syncytial virus detection in raw wastewater and presence in treatment plants in southeastern Germany.

Scientific reports·2025
Same author

Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.

The lancet. Gastroenterology & hepatology·2024
Same author

Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).

Oncology research and treatment·2024
Same author

Evaluating the sensitivity of droplet digital PCR for the quantification of SARS-CoV-2 in wastewater.

Frontiers in public health·2024
Same author

Enterococci, <i>Van</i> Gene-Carrying Enterococci, and Vancomycin Concentrations in the Influent of a Wastewater Treatment Plant in Southeast Germany.

Microorganisms·2024
Same author

Food and Environmental Virology: Use of Passive Sampling to Characterize the Presence of SARS-CoV-2 and Other Viruses in Wastewater.

Food and environmental virology·2023
Same journal

Future Challenges of Molecular Imaging in Oncology.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Clinical Applications of Theranostics.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Internal Radiation Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

The Role of Molecular Imaging in Ion Beam Therapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Molecular Imaging in Photon Radiotherapy.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
Same journal

Advancements in Intraoperative Imaging for Enhanced Surgical Precision.

Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer·2026
See all related articles

Related Experiment Video

Updated: Feb 7, 2026

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
09:48

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

7.9K

Erlotinib.

Martin Steins1, Michael Thomas2, Michael Geißler3

  • 1Clinic for Thoracic Diseases, University of Heidelberg, Röntgenstr. 1, 69126, Heidelberg, Germany. martin.steins@med.uni-heidelberg.de.

Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer
|August 3, 2018
PubMed
Summary
This summary is machine-generated.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, like erlotinib, show efficacy in treating cancers such as non-small cell lung and pancreatic cancer. Clinical data highlight their applications, effectiveness, and toxicity, alongside predictive response markers.

Keywords:
Epidermal growth factor receptorErlotinibTyrosine kinase inhibitor

More Related Videos

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.2K
Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells
08:35

Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells

Published on: August 24, 2018

13.6K

Related Experiment Videos

Last Updated: Feb 7, 2026

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques
09:48

Discrimination and Characterization of Heterocellular Populations Using Quantitative Imaging Techniques

Published on: June 30, 2017

7.9K
Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

2.2K
Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells
08:35

Hyaluronic-Acid Based Hydrogels for 3-Dimensional Culture of Patient-Derived Glioblastoma Cells

Published on: August 24, 2018

13.6K

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Epidermal growth factor receptor (EGFR) signaling is crucial in cancer development, regulating proliferation, migration, and survival.
  • EGFR's tyrosine kinase activity is a key driver of tumor progression and a significant therapeutic target.

Purpose of the Study:

  • To review clinical data on EGFR tyrosine kinase inhibitors, focusing on erlotinib.
  • To discuss the efficacy, toxicity, and predictive markers for erlotinib in various cancers, especially non-small cell lung and pancreatic cancer.

Main Methods:

  • Review of clinical trial data and scientific literature on EGFR tyrosine kinase inhibitors.
  • Analysis of erlotinib's clinical applications, efficacy, and safety profiles.

Main Results:

  • EGFR tyrosine kinase inhibitors have demonstrated significant efficacy in clinical settings.
  • Erlotinib is an approved small molecule inhibitor with established clinical applications.
  • Predictive markers for treatment response are crucial for optimizing patient outcomes.

Conclusions:

  • EGFR tyrosine kinase inhibition represents a valuable therapeutic strategy in oncology.
  • Further research into predictive markers will enhance the personalized application of EGFR inhibitors like erlotinib.